alere determine™ hiv-1/2 ag/ab combo
אורג'ניקס בע"מ - צוות טכני - in vitro, visually read, qualitative immunoassay for the simultaneous detection of free non immunocomplexed hiv-1 p24 antigen (ag) and antibodies (ab) to hiv-1 and hiv-2 in human blood.
דר נונה קרם לילה לסוג דם ab
אדוארד גאונט מעבדות קוסמטיקה בעמ - קרם לפנים
immunocomb® ii hiv 1 & 2 trispot ag-ab
orgenics ltd. - רופא - ראה הוראות שימוש
אמרייד 150 מקג
neopharm ltd, israel - epinephrine as tartrate - תמיסה להזרקה - epinephrine as tartrate 1 mg / 1 ml - epinephrine
אמרייד 300 מקג
neopharm ltd, israel - epinephrine as tartrate - תמיסה להזרקה - epinephrine as tartrate 1 mg / 1 ml - epinephrine
אמרייד 500 מקג
neopharm ltd, israel - epinephrine as tartrate - תמיסה להזרקה - epinephrine as tartrate 1 mg / 1 ml - epinephrine
נקסיום טבליות 20 מג
taro international ltd, israel - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.
נקסיום טבליות 20 מג
astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.
נקסיום טבליות 40 מג
taro international ltd, israel - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.
נקסיום טבליות 40 מג
astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.